Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8036071004
Share Class Description:
STU:AB3A: Ordinary SharesCompare
Compare
Traded in other countries / regions
SRPT.USAAB3A.GermanyS1RP34.Brazil0L35.UK IPO Date
2009-04-29Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.2 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 1.63 | |||||
| Debt-to-EBITDA | -3.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.41 | |||||
| Beneish M-Score | -1.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.8 | |||||
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 30.8 | |||||
| 3-Year Book Growth Rate | -1.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 63.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.14 | |||||
| 9-Day RSI | 25.25 | |||||
| 14-Day RSI | 34.17 | |||||
| 6-1 Month Momentum % | 1.93 | |||||
| 12-1 Month Momentum % | -0.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.95 | |||||
| Quick Ratio | 3.45 | |||||
| Cash Ratio | 2.56 | |||||
| Days Inventory | 582.86 | |||||
| Days Sales Outstanding | 81.87 | |||||
| Days Payable | 274.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.7 | |||||
| Shareholder Yield % | 0.12 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.91 | |||||
| Operating Margin % | -21.54 | |||||
| Net Margin % | -43.11 | |||||
| FCF Margin % | -47.47 | |||||
| ROE % | -77.39 | |||||
| ROA % | -17.08 | |||||
| ROIC % | -27.74 | |||||
| ROC (Joel Greenblatt) % | -114.46 | |||||
| ROCE % | -19.26 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 33.44 | |||||
| PS Ratio | 8.71 | |||||
| PB Ratio | 12.71 | |||||
| Price-to-Tangible-Book | 13.17 | |||||
| EV-to-EBIT | -21.39 | |||||
| EV-to-Forward-EBIT | 22.99 | |||||
| EV-to-EBITDA | -23.49 | |||||
| EV-to-Forward-EBITDA | 20.86 | |||||
| EV-to-Revenue | 8.57 | |||||
| EV-to-Forward-Revenue | 5.62 | |||||
| EV-to-FCF | -18.11 | |||||
| Price-to-Median-PS-Value | 0.3 | |||||
| Price-to-Net-Current-Asset-Value | 62.82 | |||||
| Earnings Yield (Greenblatt) % | -4.68 | |||||
| FCF Yield % | -5.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,152.653 | ||
| EPS (TTM) (€) | -5.456 | ||
| Beta | 0.31 | ||
| Volatility % | 69.82 | ||
| 14-Day RSI | 34.17 | ||
| 14-Day ATR (€) | 1.516764 | ||
| 20-Day SMA (€) | 115.5025 | ||
| 12-1 Month Momentum % | -0.22 | ||
| 52-Week Range (€) | 63.4 - 144.25 | ||
| Shares Outstanding (Mil) | 93.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sarepta Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(STU:AB3A)'s stock price today?
The current price of STU:AB3A is €109.30. The 52 week high of STU:AB3A is €144.25 and 52 week low is €63.40.
When is next earnings date of Sarepta Therapeutics Inc(STU:AB3A)?
The next earnings date of Sarepta Therapeutics Inc(STU:AB3A) is 2024-05-02 Est..
Does Sarepta Therapeutics Inc(STU:AB3A) pay dividends? If so, how much?
Sarepta Therapeutics Inc(STU:AB3A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers